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Abstract
Background: Macrophage activation syndrome (MAS) is a severe and potentially lethal complication of several
inflammatory diseases but seems particularly linked to systemic juvenile idiopathic arthritis (sJIA). Standardized
diagnostic and treatment guidelines for MAS in sJIA are currently lacking. The aim of this systematic literature
review was to evaluate currently available literature on diagnostic criteria for MAS in sJIA and provide an overview
of possible biomarkers for diagnosis, disease activity and treatment response and recent advances in treatment.
Methods: A systematic literature search was performed in MEDLINE, EMBASE and Cochrane. 495 papers were
identified. Potentially relevant papers were selected by 3 authors after which full text screening was performed. All
selected papers were evaluated by at least two independent experts for validity and level of evidence according to
EULAR guidelines.
Results: 27 papers were included: 7 on diagnosis, 9 on biomarkers and 11 on treatment. Systematic review of the
literature confirmed that there are no validated diagnostic criteria for MAS in sJIA. The preliminary Ravelli criteria,
with the addition of ferritin, performed well in a large retrospective case-control study. Recently, an international
consortium lead by PRINTO proposed a new set of diagnostic criteria able to distinguish MAS from active sJIA and/
or infection with superior performance.
Other promising diagnostic biomarkers potentially distinguish MAS complicating sJIA from primary and virus-
associated hemophagocytic lymphohistiocytosis.
The highest level of evidence for treatment comes from case-series. High dose corticosteroids with or without
cyclosporine A were frequently reported as first-line therapy. From the newer treatment modalities, promising
responses have been reported with anakinra.
Conclusion: MAS in sJIA seems to be diagnosed best by the recently proposed PRINTO criteria, although prospective
validation is needed. Novel promising biomarkers for sJIA related MAS are in need of prospective validation as well,
and are not widely available yet. Currently, treatment of MAS in sJIA relies more on experience than evidence based
medicine. Taking into account the severity of MAS and the scarcity of evidence, early expert consultation is
recommended as soon as MAS is suspected.
Keywords: SJIA, MAS, Hemophagocytosis, Systemic, Arthritis, Complications, Diagnosis, Treatment, Biomarkers, HLH
* Correspondence: v_boom@hotmail.com
1Department of Pediatric Rheumatology, Wilhelmina Children’s Hospital,
University Medical Center Utrecht, Utrecht, The Netherlands
Full list of author information is available at the end of the article
© 2015 Boom et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Boom et al. Pediatric Rheumatology  (2015) 13:55 
DOI 10.1186/s12969-015-0055-3
Background
Macrophage activation syndrome (MAS) is an intriguing
and potentially life-threatening condition [1, 2], clinically
characterized by non-remitting fever, hepatosplenome-
galy, lymphadenopathy, encephalopathy, coagulopathy
and even multi organ failure in severe cases. Laboratory
abnormalities of MAS include pancytopenia, hyperferri-
tinemia, hypertriglyceridemia and elevated serum trans-
aminases [3]. MAS has been reported to occur in the
context of infectious-, malignant-, metabolic- and auto-
immune diseases [4] but seems particularly linked to
systemic Juvenile Idiopathic Arthritis (sJIA), occurring in
at least 7–13 % of sJIA patients [1, 5, 6]. The actual inci-
dence of MAS in sJIA is likely to be even higher, as bone
marrow evidence of subclinical MAS was found in more
than 53 % of sJIA patients at the time of diagnosis [5].
SJIA is a subtype of Juvenile Idiopathic Arthritis (JIA)
and is characterised by arthritis of unknown origin and
extra-articular symptoms like spiking fever, often accom-
panied with a macular rash, serositis, hepatosplenome-
galy and generalised lymphadenopathy due to
reticuloendothelial involvement. SJIA is considered an
(acquired) auto-inflammatory disease rather than an
autoimmune disease because of clear clinical and patho-
physiological differences when compared to the other
subtypes of JIA. Moreover, sJIA lacks clear association
with HLA-types or auto-antibodies. Pathophysiologically,
it is now clear that mechanisms related to the innate im-
mune system, especially driven by IL-1, IL-6 and IL-18,
are pivotal in sJIA [7, 8]. Its disease course can be un-
predictable, varying from a monophasic course of rela-
tively mild disease to chronic relapsing periods of severe
poly-arthritis accompanied by critical extra-articular
symptoms and complications causing significant morbid-
ity and mortality.
Nowadays, MAS in sJIA is considered an acquired or
secondary hemophagocytic lymphohistiocytic (HLH) dis-
order [9]. In primary HLH, defective control of T cell ac-
tivation, including in many cases defects in the NK cell
cytolytic pathway, underlies uncontrolled cytokine pro-
duction resulting in excessive activation and tissue inva-
sion of T lymphocytes and macrophages. The enormous
cytokine storm and blood cell hemophagocytosis by
CD163+ macrophages are likewise responsible for the
clinical and laboratory features of HLH and resemble
those of MAS in sJIA [4]. Moreover, the strong associ-
ation of MAS with sJIA hints to shared pathophysio-
logical mechanisms with the other HLH-syndromes.
Diagnostic guidelines for (acquired) HLH are available
(HLH-2004) [10] which are sometimes used for diagno-
sis of MAS in sJIA.
Diagnosis of MAS in sJIA patients can be challenging
since MAS is difficult to distinguish from a flare of sJIA
or from sepsis [1, 6, 11] and certain treatments of sJIA,
such as tocilizumab, can conceivably mask the clinical
and biologic features of MAS,[12]. Moreover, treatment
is generally based on the practitioner's experience. The
aim of this systematic literature review was therefore to
evaluate published sets of diagnostic criteria for MAS in
sJIA and provide an overview of possible biomarkers for
diagnosis, disease activity and treatment response. In
addition, the literature was searched for published data
on treatment of MAS.
Methods
A first systematic literature search was conducted on the
1st of June 2014, comprising all English articles from
1970 onwards in the MEDLINE, EMBASE and Cochrane
databases. MEDLINE was searched through Pubmed by
searching for the medical subject headings (MeSH)
(Arthritis, Juvenile Rheumatoid), (Lymphohistiocytosis,
Hemophagocytic) and (Macrophage Activation Syn-
drome) supplemented with the keywords JIA, JRA, Still’s
disease, MAS, lymphohistiocytosis and synonyms. For
EMBASE, MeSH terms were replaced by the corre-
sponding Emtree terms. The Cochrane Central Register
of Controlled Trials (CENTRAL) was searched for the
same keywords. Search strings were built under supervi-
sion of specialized librarians and validated for complete-
ness by performing cited reference checks
(www.scopus.com). Exclusion criteria were adult studies,
case-reports, case-series containing less than 3 cases,
meeting abstracts, reviews and articles not considering
diagnosis, biomarkers or therapy of MAS in sJIA. In-
cluded articles were initially selected based on title and
abstract by two authors separately, after which full text
screening was performed. For every paper, the category
of evidence was determined by two reviewers according
to EULAR guidelines [13]. In case of disagreement on
in- or exclusion of a paper or category of evidence, the
full text was discussed in the team to reach consensus.
During the review process of this paper a second litera-
ture search was conducted on September 22nd, 2015
allowing inclusion of the most recently published papers.
The search strategy and inclusion methods were identi-
cal to the first search. The category of evidence of all pa-
pers additionally included in the second search was
evaluated by two authors (SV and NW).
Results
A total of 495 potentially relevant titles were identi-
fied through two literature searches, of which 36 pa-
pers were retrieved for full text screening (Fig. 1). In
total, we included 27 eligible papers: 7 on diagnosis,
9 on biomarkers and 11 on treatment [Table 1]. The
level of evidence (LOE) of included papers is listed in
Table 1. Nine papers were excluded after full text
screening. Two papers on biomarkers were excluded
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because data of sJIA patients with MAS were insepar-
ably mixed with MAS in the context of other under-
lying diseases [14, 15]. 7 papers assessing genetic
associations of MAS in sJIA were excluded because
these papers addressed possible genetic associations
as possible underlying causes rather than as possible
biomarkers for diagnosis, disease activity or treatment
response. Of note, one paper describing disease fea-
tures as well as treatments used worldwide [16] was
only included in the diagnosis section of this review,
since specific information on (effectivity of ) thera-
peutic regimens used is not listed.
Diagnosis of MAS in sJIA
Seven papers were found on diagnostic criteria for MAS
in sJIA [Table 1]. The level of evidence of the included
papers was 3, except when listed otherwise [Table 1]. In
2005, Ravelli et al. proposed preliminary diagnostic
guidelines based on clinical and laboratory parameters,
established to differentiate between MAS and flare of ac-
tive sJIA [3]. The combination of variables with the
highest ability to distinguish between disease and con-
trols was obtained by a statistical approach [17]. Pres-
ence of any 2 or more laboratory or of any 2 or more
clinical and/or laboratory criteria was required for the
diagnosis of MAS [Table 2].
The performance of the preliminary diagnostic criteria
by Ravelli was assessed by Davi and co-workers, in a
multinational initiative lead by the Pediatric Rheumatol-
ogy International Trials Organization (PRINTO). This
collaboration evaluated a large retrospective cohort of
sJIA patients with MAS (362 patients), sepsis (345 pa-
tients) and active sJIA patients without MAS (404 pa-
tients) and compared the performance of the
preliminary Ravelli criteria to the HLH-2004 diagnostic
guidelines to differentiate MAS in sJIA from a flare of
sJIA and sepsis [18]. Within this cohort, the preliminary
diagnostic criteria performed best at differentiating MAS
in sJIA from a flare of sJIA (sensitivity 86 %, specificity
86 %, κ 0.71) or infection (by adding hyperferritinemia
(≥500 ng/ml) as a parameter (sensitivity 86 %, specificity
95 %, κ 0.76)).
In continuation of this collaboration, Minoia et al
compared clinical and laboratory parameters of the 362
patients with sJIA associated MAS [16]. More than 90 %
of patients showed decreased platelet counts and in-
creased aspartate aminotransferase, triglycerides, ferritin
and lactate dehydrogenase levels during onset of MAS
[16]. Importantly, serum ferritin was the laboratory
marker showing the largest change in pre-MAS and
MAS-onset values. This group also showed that labora-
tory features of MAS were comparable across patients
registered from different geographic locations [19].
Importantly, the PRINTO collaboration also aimed to
develop a new set of diagnostic criteria through a multi-
step process. First, candidate diagnostic criteria were
identified from a questionnaire, listing 28 clinical, la-
boratory and histopathological features that was sent to
505 paediatric rheumatologists worldwide [20]. Partly
based upon the results of this questionnaire, a new set
of (laboratory) diagnostic criteria was proposed by
PRINTO in 2015 to distinguish MAS in sJIA from MAS
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Fig. 1 Flow chart of the systematic review process
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Table 1 Included papers on diagnosis, biomarkers and treatment of MAS in sJIA patients
Authors Year Number
of sJIA
patients
with MAS
Subject Content Evaluation
design
Results Conclusion Limitations LOE
[13]
Ravelli
et al.[3]
2005 74 diagnosis Diagnostic criteria of
MAS
Comparative
study
A set of preliminary clinical and
laboratory criteria of MAS in sJIA.
Preliminary Ravelli criteria
[Table 3].
Not validated, lacks ferritin as
parameter.
3
Davi
et al.[18]
2014 362 diagnosis Assessment of
performance of
diagnostic guidelines
Retrospective
study
The preliminary Ravelli criteria
perform better than the HLH-
2004 guidelines in differentiating
MAS from active sJIA or infection
(by adding ferritin as parameter).
The preliminary diagnostic
criteria perform better than the
HLH-2004 guidelines.
Retrospective study design,
selection bias
3
Minoia
et al.[16]
2014 362 diagnosis Disease features of MAS
in sJIA
Descriptive
study
Decreased platelet counts and
increased ASAT, triglycerides,
ferritin and LDH levels were the
most common laboratory
features during onset of MAS.
Fever and organomegaly were
the most frequent clinical
symptoms.
The clinical spectrum of MAS in
sJIA comprises frequently
reported clinical and laboratory
features.
Retrospectively collected data,
possible selection bias.
3
Minoia
et al.[19]
2015 362 diagnosis Clinical heterogeneity of
MAS in sJIA
Descriptive
study
Clinical and laboratory features of
MAS in sJIA did not differ among
patients registered from different
geographic locations.
The clinical spectrum of MAS is
comparable across patients from
different geographic locations.
Retrospectively collected data,
possible selection bias.
3
Ravelli
et al.[21]
2015 362 diagnosis Cross-validated
literature- and
consensus based
diagnostic guidelines for
MAS in sJIA
Comparative
study
complemented
with expert
opinion
A final set of diagnostic
(laboratory) criteria was approved
based on the selection of best
classification criteria through
statistical analyses and consensus
formation techniques with a
higher sensitivity and specificity
compared to the preliminary
Ravelli criteria.
Best performing set of diagnostic
criteria for MAS in sJIA [Table 3].
Not prospectively validated, level
of evidence low due to
incorporation of expert opinion.
3/4
Kostik
et al.[22]
2015 18 diagnosis Diagnostic criteria Comparative
study
Laboratory criteria were more
precise in discriminating MAS
from active sJIA than clinical
variables. Eight widely available
laboratory markers were selected
as best for early identification of
MAS.
Preliminary diagnostic criteria. Retrospective, no evaluation of
changes in laboratory
parameters.
3
Lehmberg
et al.[23]
2013 27 diagnosis Differentiating MAS in
sJIA from HLH
Retrospective
study
Generally available laboratory
measures with accessory cut-off
values to distinguish MAS
complicating sJIA from primary
HLH and virus-associated HLH
(VA-HLH) were retrospectively
identified.
Neutrophil counts >1.8 x 109/L,
CRP >90 mg/L and sCD25 <7900
U/ml indicate MAS in sJIA rather
than primary HLH or VA-HLH.
No control group, no cut-off
points.
3
Grom
et al.[24]
2002 7 biomarkers NK cell function Comparative
study
NK cell activity was decreased in
all patients compared to healthy
NK dysfunction is common in
sJIA associated MAS
Small patient sample. 3
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Table 1 Included papers on diagnosis, biomarkers and treatment of MAS in sJIA patients (Continued)
controls. Low NK cell activity was
associated with decreased
numbers of NK cells.
Bleesing
et al.[25]
2007 7 biomarkers sCD25, sCD163 Comparative
study
sCD25 and sCD163 were
significantly higher in the acute
phase of MAS compared to
untreated new-onset sJIA
patients and correlated with
disease activity.
sCD35 and sCD163 are promising
biomarkers of MAS
Small number of patients, not
validated
3
Reddy
et al.[26]
2014 2 biomarkers sCD25, sCD163 as
markers of subclinical
MAS in active sJIA
Comparative
study
Laboratory abnormalities
associated with MAS were seen
in active sJIA patients with
elevated levels of sCD25 and to a
lesser extend in patients with
elevated levels of sCD163.
sCD25 might be a marker of
subclinical MAS in active sJIA.
Only 2 MAS patients, not
validated
3
Gorelic
et al.[27]
2013 7 biomarkers FSTL-1, ferritin/ESR ratio Comparative
study
FSTL-1 levels during MAS are
elevated compared to active sJIA.
Elevated levels of FSTL-1 were
associated with occult MAS,
correlated with levels of sCD25
and ferritin and normalized after
treatment. Ferritin/ESR ratio was
superior to ferritin in
discriminating MAS from new-
onset sJIA.
Elevated levels of FSTL-1 might
be a marker of occult MAS.
FSTL-1 is unspecific, small sample
size, not validated
3
Shimizu
et al.[8]
2010 5 biomarkers IL-6, IL-18, neopterin for
differentiating MAS in
sJIA from VA-HLH or KD
Comparative
study
IL-18 was significantly higher in
MAS in sJIA compared to EBV-
HLH or KD and correlated with
measures of disease activity. IL-6
was higher in KD patients and
neopterin was higher in EBV-
HLH.
Serum cytokine profiles differ
between MAS in sJIA, KD and
EBV-HLH. IL-18 might be useful
for differentiation of MAS in sJIA
from HLH.
Small sample, not validated 3
Shimizu
et al.[12]
2012 5 biomarkers IL-18, IL-6 during TCZ
treatment
Comparative
study
TCZ can suppress clinical
symptoms of MAS. IL-18 and
IL-6 were elevated during MAS
in patients with and without TCZ
and correlated with disease
activity.
During TCZ treatment,
monitoring IL-18 and IL-6 could
be useful to disclose early MAS.
Only 5 MAS patients, not
validated
3
Yokota
et al.[28]
2015 14 biomarkers Changes in laboratory
markers in patients with
MAS receiving TCZ
Retrospective
Descriptive
study
Most patients had common
laboratory features associated
with MAS.
Clinical and laboratory features of
MAS appear similar among
patients with and without TCZ
treatment.
No control group, retrospective 3
Shimizu
et al.[29]
2015 15 biomarkers Serum IL-18 as bio-
marker for the predic-
tion of MAS in sJIA
Comparative
study
During active sJIA, IL-18 levels
>47750 pg/ml predicted
development of MAS. IL-6 levels
in patients with MAS did not
differ from IL-6 levels during
active sJIA in absence of MAS.
Serum IL-18 levels > 47750 pg/
ml might be a biomarker for
MAS development
High cut-off values suggest low
sensitivity
3
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Table 1 Included papers on diagnosis, biomarkers and treatment of MAS in sJIA patients (Continued)
Kounami
et al.[30]
2005 5 biomarkers urine β2-microglobulin Descriptive
study
Urinary β2-microglobulin levels
increased during MAS.
Increases in urinary β2-
microglobuline might be an
indicator of MAS.
No control group, small sample
size, not specific
3
Sawhney
et al.[6]
2001 8 treatment steroids, CsA, eto Case-series Patients received steroids as part
of a combinational regimen, of
which >62% in combination with
CsA.
High dose steroids in
combination with CsA was
effective in cases of MAS.
Small retrospective case-series 3
Mouy
et al.[35]
1996 5 treatment steroids, CsA Case-series CsA monotherapy was effective
in 7 episodes of MAS and was
effective in 3 episodes of steroid-
resistant MAS.
CsA can be effective as first or
second line (mono) therapy.
Small retrospective case-series 3
Stephan
et al.[1]
2001 18 treatment steroids, CsA, IVIG, eto Case-series CsA as initial monotherapy
induced remission in 5 cases.
CsA was effective in 6 cases of
steroid-resistant MAS. Steroids
were effective as first-line (mono)
therapy. IVIG was not effective.
CsA and steroids were effective
as first-line monotherapy or
combined.
Small retrospective case-series 3
Miettunen
et al.[37]
2011 8 treatment Anakinra Case-series Anakinra was effective in 8 cases
of conventional therapy- resistant
MAS.
Anakinra was effective in cases
where initial therapy with
steroids and CsA failed.
Small retrospective case-series 3
Ramanan
et al.[31]
2004 3 treatment (pulse) steroids, eto Case-series Steroid monotherapy was
effective in 3 patients with MAS
with renal involvement.
Steroids can be effective as
monotherapy in patients with
renal involvement complicating
MAS.
Small retrospective case-series 3
Lin et al.[2] 2012 4 treatment steroids, IVIG, CsA Case-series Prednisolone was effective as
monotherapy or in combination
with CsA. IVIG was not effective.
Patients responded well to
steroids and CsA.
Small retrospective case-series 3
Kounami
et al.[30]
2005 5 treatment steroids, IVIG, CsA Case-series All patients treated with CsA as
first or second line therapy
responded well. IVIG failed as
first-line treatment.
CsA was effective as first-line
(mono) therapy.
Small retrospective case-series 3
Singh
et al.[11]
2011 6 treatment steroids, IVIG Case-series Four patients responded to high
dose methylprednisolone, 1
patient recovered after addition
of IVIG to steroids.
Steroids were effective as initial
monotherapy.
Small retrospective case-series 3
Cortis
et al.[36]
2006 9 treatment steroids, CsA, etanercept Case-series 7 cases of MAS responded to
high dose steroids with or
without CsA. In one patient, a
third episode of MAS responded
Patients responded well to
steroids and CsA.
Small retrospective case-series 3
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Table 1 Included papers on diagnosis, biomarkers and treatment of MAS in sJIA patients (Continued)
to etanercept when steroids and
CsA failed.
Zeng
et al.[32]
2008 13 treatment steroids, eto, VCR, IVIG Case-series Steroids were effective as first-
line (mono) therapy. 1 patient
responded to eto after steroids,
CsA and IVIG failed.
Steroids were effective as
first-line (mono) therapy.
Small retrospective case-series 3
Nakagishi
et al.[34]
2014 3 treatment Dexamethasone
palmitate
Case-series All three patients were resistant
to methylprednisolone but
responded well to
dexamethasone palmitate.
DexP can be effective in mps-
resistant MAS.
Small case-series 3
Abbreviations: LOE level of evidence; MAS Macrophage Activation Syndrome; sJIA systemic juvenile idiopathic arthritis; ASAT aspartate aminotransferase; LDH lactate dehydrogenase; HLH hemophagocytic
lymphohistiocytosis; CRP C-reactive protein; VA-HLH virus-associated hemophagocytic lymphohistiocytosis; FSTL-1 Follistatin-related protein 1; ESR erythrocyte sedimentation rate; EBV-HLH Epstein-Barr related hemopha-
gocytic lymphohistiocytosis; KD Kawasaki disease; TCZ Tocilizumab; CsA cyclosporine A; VCR vincristine; IVIG intravenous immunoglobulin; eto etoposide; DexP Dexamethasone palmitate
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imitating conditions (LOE 3–4) [21]. Expert consensus
procedures were carried out for distinguishing MAS in
sJIA from non-MAS whereupon expert consensus was
considered as diagnostic ‘golden standard’. A final set of
diagnostic criteria was approved based on the selection
of best classification criteria through statistical analyses
and consensus formation techniques with an 82 % con-
sensus among 28 international experts. These laboratory
parameters are listed in Table 3. Cross-validation of
these criteria was performed by comparing the perform-
ance of these criteria to the expert opinion ‘golden
standard’ in the entire patients database of 1.111 patients
and showed a sensitivity of 0.72, a specificity of 0.97, a
positive predictive value of 93.9 %, a negative predictive
value of 84.8 %, an area under the curve of 0.84 and a
kappa for agreement of 0.72.
Also Kostik et al. created preliminary diagnostic guide-
lines for early discrimination of MAS in patients with
active sJIA [22]. Clinical and laboratory features of 18
patients with active sJIA with MAS and 40 patients with
active sJIA without MAS were reviewed and compared
retrospectively. Laboratory criteria were more precise in
discriminating MAS from active sJIA than clinical vari-
ables. Eight widely available laboratory markers with cut-
off points were selected as best for early identification of
MAS: white blood cell counts ≤9.9 × 109/L, platelet
counts ≤211 × 109/L, aspartate aminotransferase >59.7
U/L, lactate dehydrogenase > 822 U/L, albumin <29 g/L,
ferritin >400 μg/L, fibrinogen ≤1.8 g/L and the presence
of proteinuria. Presence of 3 and more criteria provided
the highest specificity and sensitivity (1.0, 1.0) with the
highest odds ratio (2997 (57-156963) in the whole
model.
MAS can be the presenting feature of sJIA even prior
to onset of characteristic symptoms like arthritis. In
2013, Lehmberg et al. retrospectively identified generally
available laboratory measures with accessory cut-off
values to distinguish MAS complicating sJIA from pri-
mary HLH and virus-associated HLH (VA-HLH) [23].
Data from sJIA patients that presented with MAS as ini-
tial feature of sJIA was obtained from the German na-
tional HLH study centre. Neutrophil counts >1.8 × 109/L
(sensitivity 85 %, specificity 83 %), CRP >90 mg/L (74 %,
89 %) and sCD25 < 7900 U/ml (79 %, 76 %) indicated
MAS in sJIA rather than primary HLH or VA-HLH.
Novel biomarkers of MAS in sJIA
For this review, we identified 9 eligible studies on prom-
ising biomarkers for MAS in sJIA. All papers were cat-
egory of evidence 3 [Table 1] and studied 1 or more
(inflammatory) biomarkers for diagnostic potential in
sJIA related MAS.
Grom et al. assessed NK cell function in 7 sJIA pa-
tients with MAS by a standard 51Cr-release assay [24].
NK cell activity was decreased in all patients compared
to healthy controls. Furthermore, low NK cell activity
was associated with decreased numbers of NK cells.
Bleesing et al. demonstrated soluble IL-2 receptor α
chain (sIL-Rα, or sCD25) and soluble CD163
(sCD163) to be significantly higher in the acute phase
of MAS compared to untreated new-onset sJIA pa-
tients [25]. Moreover, sCD25 and sCD163 levels were
found to correlate with disease activity. In a subgroup
of patients (n = 3) CD163 could also be stained in in-
creased levels in bone marrow specimens. Within
their population of 7 sJIA patients with MAS and 16
new-onset sJIA patients without MAS, they identified
a subgroup of new-onset sJIA patients with elevation
of at least one of these markers to levels associated
with overt MAS. Interestingly, these patients had sig-
nificantly higher levels of ferritin, normal platelet
counts, lower haemoglobin levels, and lower NK cell
function compared to the other new-onset patients.
As these features resemble features of MAS, it was
suggested that assessment of sCD25 and sCD163
levels could identify subclinical MAS.
Reddy et al. recently assessed levels of sCD25 and
sCD163 in active sJIA patients (n = 33) and 2 sJIA pa-
tients with MAS [26]. They found multiple laboratory
abnormalities suggestive of MAS in their patient groupTable 2 Preliminary diagnostic guidelines for MAS complicating
sJIA [3]
Clinical criteria
1. Central nervous system dysfunction
2. Haemorrhages
3. Hepatomegaly
Laboratory criteria
1. Decreased platelets count (≤262 × 109/L)
2. Elevated levels of aspartate aminotransferase (>59 U/L)
3. Decreased white blood cell count (≤4.0 × 109/L)
4. Hypofibrinogenemia (≤2.5 g/L)
Presence of any 2 or more laboratory or of any 2 or more clinical and/or
laboratory criteria is required for the diagnosis of MAS in sJIA
Table 3 PRINTO diagnostic criteria for MAS in sJIA [21]
A patient with (suspected) sJIA with
Fever and serum ferritin > 684 ng/ml
AND any 2 of the following
Platelet count ≤181 × 109/L
Aspartate aminotransferase (>48 U/L
Triglycerides > 156 mg/dl
Fibrinogen ≤360 mg/dl
Laboratory abnormalities should not be otherwise explained by the patient’s
condition, such as concomitant immune-mediated thrombocytopenia,
infectious hepatitis, visceral leishmaniasis, or familial hyperlipidemia
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with the highest sCD25 and sCD163 levels. In contrast
to sCD163 levels, sCD25 levels correlated significantly
with CRP, Hb and LDH.
Gorelik et al. reported Follistatin-related protein 1
(FSTL-1) levels to be elevated in active sJIA and to be
even more elevated during MAS [27]. In their cohort of
27 sJIA patients including 7 patients with MAS, elevated
levels of FSTL-1 were associated with occult MAS, cor-
related with levels of sCD25 and ferritin and normalized
after treatment. In addition, in an effort to find bio-
markers distinguishing between MAS and new-onset
sJIA, a ferritin to ESR ratio > 80 had the highest sensitiv-
ity and specificity (100 %, 100 %) in their cohort.
Shimizu et al. studied cytokines during MAS in serum
of sJIA patients and compared them to cytokine patterns
in EBV-induced HLH (EBV-HLH), Kawasaki disease
(KD) and healthy age matched controls [8] IL-18 con-
centrations during MAS were significantly higher com-
pared to EBV-HLH and KD and were found to correlate
to measures of disease activity (CRP, ferritin, LDH and
other cytokines). In addition, serum neopterin and
sTNF-RII levels were significantly higher during MAS
compared to flares of sJIA. IL-6 concentrations in pa-
tients with KD were significantly higher compared to
EBV-HLH or MAS patients, whereas high neopterin
concentrations hinted toward EBV-HLH rather than
MAS or KD.
In a subsequent study following up on this, Shimizu et
al. studied IL-18 and IL-6 for MAS in sJIA during Toci-
lizumab (TCZ) treatment [12]. Although TCZ was able
to suppress clinical symptoms of active sJIA and MAS,
IL-18 and IL-6 were consistently elevated during periods
of MAS. Moreover, both in patients with and without
TCZ, IL-18 and IL-6 levels correlated with disease activ-
ity and increased consistently before elevation of other
inflammatory parameters. This suggests that during TCZ
treatment, monitoring these cytokines could be useful to
disclose MAS in an early phase, possibly before onset of
overt clinical symptoms.
Yokota et al. studied the 25 cases of MAS that were
reported in a phase IV registry of sJIA patients receiving
TCZ in Japan [28]. One aim of this study was to confirm
changes in laboratory markers suggestive of MAS in pa-
tients with MAS during TCZ treatment. Diagnosis of
MAS was re-evaluated in every patient on the basis of
reported clinical and laboratory data by a committee
comprised of 2 pediatric rheumatologists, 1 pediatric
specialist in infectious diseases, 1 pediatric cardiologist
and 1 adult rheumatologist. 15 cases were considered as
definite or probable MAS, 2 cases as EBV-HLH and 8
cases as possible MAS or non-MAS. Although not spe-
cified, the authors report that common clinical and la-
boratory findings suggestive of MAS were observed in
the definite or probable MAS group and suggest that
clinical and laboratory features (like platelets, liver en-
zymes, coagulation markers and ferritin) of MAS appear
similar among patients with and without TCZ
treatment.
In another recent case-control study, Shimizu et al.
studied the clinical significance IL-6 and IL-18 in serum
of sJIA patients for predicting MAS [29]. Levels of IL-6
and IL-18 were measured in serum of 76 sJIA patients
with active disease of which 15 patients developed MAS.
During MAS, IL-18 levels were significantly higher com-
pared to patients without MAS. Interestingly, the pa-
tients with active sJIA who developed MAS during the
course of the disease had significantly higher serum IL-
18 levels compared to those who did not develop MAS
[29]. During active sJIA, serum IL-18 levels >47750 pg/
ml predicted development of MAS (sensitivity 86.7 %,
specificity 70.5 %). Serum IL-6 levels in patients with
MAS did not differ from IL-6 levels during active sJIA in
absence of MAS.
Kounami et al. reported highly elevated levels of β2-
microglobulin in serum and urine of sJIA patients dur-
ing episodes of MAS [30]. Although assessed in a small
uncontrolled population, comparative measures pre-
MAS and during MAS showed an evident rise in urine
β2-microglobulin, even in absence of change of other in-
flammatory parameters.
Treatment of MAS in sJIA
Currently, there are no validated evidence based treat-
ment guidelines on MAS in sJIA. However, our literature
search identified 11 papers elaborating on treatment of
MAS in sJIA. All papers were retrospective clinical case-
series, category of evidence 3 [13], comprising 96 epi-
sodes of MAS in a total of 78 sJIA patients.
High-dose corticosteroid therapy was frequently re-
ported effective as first-line treatment [1, 2, 6, 11, 30–
32]. Thirty-four reported episodes of MAS reached full
remission on initial steroid monotherapy [1, 2, 11, 30,
31], with remission rates up to 68 % [11, 32]. Although
disease severity was not reported consistently, intraven-
ous pulse therapy seemed to be the regimen of choice in
more severe cases of MAS. Steroids were reported safe
and effective in patients with renal involvement [6, 31, 33].
In one paper, dexamethasone palmitate, a liposome-
incorporated form of dexamethasone was effective in a
case of MAS that was resistant to pulse methylpredniso-
lone and as part of a combinational regimen in two other
patients [34].
Cyclosporine A (CsA), a T-cell blocking agent that has
proven its efficacy in other hystiocytic disorders, was
also reported to induce remission in the majority of
cases. CsA can be given as monotherapy [1, 30], but in
most patients was started as part of a combinational
regimen [1, 2, 6, 30, 32, 35]. Importantly, CsA was
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reported life-saving in serious cases of steroid resistant
MAS [35].
Etoposide was used in 8 sJIA patients, in every case as
part of a first- or second line combination regimen. Eto-
poside was able to induce rapid recovery in cases of ster-
oid and CsA resistant MAS [36–38]. In these case-
series, no serious adverse events were reported.
In total, 14 patients were treated with intravenous im-
munoglobulin therapy (IVIG), of which six patients re-
ceived IVIG as initial monotherapy. Remission on
monotherapy was achieved in none. For only 1 patient,
addition of IVIG to steroids resulted in remission [11].
Biologicals are increasingly used in the treatment of
MAS in sJIA. However, only 2 papers included in this re-
view addressed the use of biolocals [2, 37]. Anti-TNFα
therapy was used in two patients with unsatisfactory re-
sults [2, 37]. Importantly, Miettunen et al. reported on
12 MAS patients, including 8 sJIA patients, treated with
anakinra after insufficient response to steroids, IVIG and
CsA. Clinical and laboratorial remission was reached in
all patients in absence of any side effects. In addition,
control of underlying systemic disease was noted in all
patients at follow-up.
Discussion
MAS in sJIA is an intriguing but potentially life-
threatening condition with reported mortality rates of
22–30 % [1, 6]. Therefore, prompt diagnosis and initi-
ation of treatment is of vital importance. Critically
reviewing published literature on MAS in sJIA confirms
the notion that both diagnosis and treatment still rely
more on experience than on evidence based medicine.
There are no prospectively validated diagnostic criteria
for MAS in sJIA. Since clinical and laboratory character-
istics of MAS in sJIA resemble those of primary HLH,
diagnostic criteria designed for primary HLH(HLH-
2004) [10] have been used in diagnosing acquired forms
like MAS [32], however with limitations. For diagnosis
of MAS, at least 5 of 8 criteria, comprising more ad-
vanced tests that are not routinely performed, need to
be present. Also, cut-off values of the HLH protocol fall
in the cytopenia range and since sJIA is characterized by
high levels of leukocytes and platelets, a relative decrease
in these parameters may be more suitable for recogni-
tion of early MAS.
The preliminary diagnostic guidelines for MAS in sJIA
provided by Ravelli are increasingly used and were
proved to perform best in diagnosing MAS in sJIA in a
retrospectively evaluated cohort of 362 MAS patients
and 749 disease controls [18]. Recently, a multinational
collaborative project aimed to develop a new set of diag-
nostic criteria for MAS in sJIA has just been completed.
This has resulted in a new set of widely available labora-
tory parameters with cut-off values, including ferritin as
a parameter, and fever as obligatory clinical parameter.
Due to incorporation of expert-opinion in the method-
ology, the LOE of these criteria was considered 3 to 4.
However, considering the enormous dataset and high
validity of the methodology that underlie these criteria,
plus the fact that these criteria have already shown high
performances in a cross-validation process, the authors
of this review agree that this set of diagnostic criteria is
currently the one that is most useful for current diag-
nostic purposes, notwithstanding some limitations.
These guidelines are still in need for prospective valid-
ation. In addition, expert consensus on diagnosis was
considered the diagnostic ‘golden-standard’ and the per-
formance of these criteria in patients receiving biologics
that potentially influence laboratory parameters should
still be determined.
Also Kostik et al. identified a set of discriminating la-
boratory criteria for early discrimination of MAS in sJIA
[22]. Although retrospectively assessed in a relatively
small (single centre) population, the performance was
superior to both the HLH-2004 protocol and the Ravelli
criteria. However, these sets have never been evaluated
in the same cohort.
There is no widely accepted single biomarker for the
diagnosis and/or disease activity for MAS in sJIA. In
general, evaluation of biomarkers is complicated by the
fact that there is no validated reference test for MAS in
sJIA. However, multiple papers suggested promising and
interesting candidate biomarkers. Especially for those
patients in which MAS is the presenting symptom of
sJIA, or any other inflammatory disorder like SLE, virus-
associated HLH etc, biomarkers facilitating diagnosis
could be of critical value in clinical practice.
The soluble markers sCD25 and sCD163 are specific-
ally of interest since they both reflect prominent patho-
physiological characteristics of MAS. sCD25 reflects the
amount of T-cell activity and elevated levels have been
reported in several inflammatory conditions [39, 40]
Therefore, specificity of this biomarker might be an
issue. sCD163 is a scavenger receptor released by alter-
natively activated (M2) macrophages upon activation
[41, 42]. Elevated levels of sCD25 and sCD163 are found
in both primary and secondary forms of HLH [5, 10, 23,
30], including in MAS in sJIA [25, 26]. In small cohorts,
subgroups of sJIA patients with elevated levels of sCD25
in combination with multiple other laboratory abnor-
malities suggestive of MAS were identified [26], indicat-
ing early immunological derailment prior to the
overwhelming cytokine storm in MAS, possibly giving
justification for intensification of immunosuppressive
therapy in these patients.
Despite features of MAS in sJIA have close resem-
blance to other (primary or secondary) HLH syn-
dromes serum cytokine patterns appear to differ. IL-
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18 is elevated in active sJIA and is increasingly used
as a biomarker for diagnosis and treatment response.
Levels of IL-18 are even further increased during epi-
sodes of MAS, as are the levels of neopterin and
sTNF-RII which both are believed to reflect immune
activation [29, 43, 44]. Importantly, the increase of
IL-18 appears to be specific for MAS in sJIA as other
secondary HLH syndromes are associated with lower
levels of IL-18 [8]. Recently it was shown that IFNγ
is also markedly elevated during MAS in sJIA [14].
Currently, a multicentre long-term follow-up study is
performed to assess effectivity and safety of an anti-
IFNγ antibody as treatment of HLH [45].
Another potential biomarker is FSTL-1, a protein pro-
duced by cells of mesenchymal origin [46] that is sug-
gested to be a mediator of innate immune pathways that
underlie arthritis in sJIA [47, 48]. This inflammatory
protein is highly elevated in synovial fluid and serum of
sJIA patients [48] and several auto-immune diseases
[46]. During (occult) MAS, FSTL-1 levels are even more
elevated compared to active sJIA, indicating that FSTL-1
could be a biomarker for early diagnosis of MAS in sJIA
when replicated and validated for specificity in other
cohorts.
In primary HLH syndromes, pathogenetic mechanisms
have extensively been studied. One consistent and intri-
guing finding is impaired NK cell cytotoxic function,
often secondary to mutations in genes involved in the
perforin mediated cytolytic pathway [49–51]. Low NK
cell function is increasingly described in sJIA as well,
with profoundly depressed cytotoxic activity during epi-
sodes of MAS [50, 52]. Similar to mutations in the
PRF1, related genes including Munc 13-4, have been de-
scribed in a subset of sJIA patients [51–53], underlining
pathophysiological similarities between primary and sec-
ondary HLH like MAS. Better understanding of the rela-
tion between NK dysfunction, sJIA pathogenesis and the
development of MAS should clarity the value of NK cell
function assessment in the diagnosis of MAS and pos-
sibly the identification of patients at risk.
β2-microglobulin was the only possible biomarker
that was studied in urine. It is part of the HLA mol-
ecule and enters the bloodstream after metabolic deg-
radation. During chronic inflammation, serum levels
of β2-microglobulin can rise after reaching the renal
reabsorption threshold, as has been reported in the
active phase of hemophagocytic syndromes and MAS
in sJIA [30, 54, 55]. To study its relevance as a bio-
marker, this should now be replicated in a larger
study design including a control group.
As becomes clear from the available literature there is
no consensus on how to treat MAS in sJIA. Evidence
based guidelines are lacking and no clinical trials have
been conducted so far. Most experience is still with high
dose of systemic steroids, often combined with other (T
cell) immunosuppressive therapy [16]. In the largest
existing database of MAS cases in sJIA, almost 98 % of
the patients received corticosteroids and 61 % received
CsA [16]. Presentation of MAS can be sudden and its
course overwhelming. Therefore, physicians must aim
for immediate and profound immunosuppression. Dur-
ing MAS, low-dose steroid therapy can be inadequate [1,
35]. In our experience and in accordance with the litera-
ture, high dose ‘pulse’ methylprednisolone therapy seems
more effective. In addition to steroids, CsA was reported
safe and highly effective as first-line monotherapy and
has shown its critical value in steroid resistant MAS
[35]. Accordingly, CsA plus systemic steroids, seems a
fair first choice in the treatment of MAS Of note, CsA
does not seem to influence underlying systemic disease
and it is unknown for how long the treatment should be
continued after clinical improvement. Consequently,
flares of MAS have been reported after abrupt termin-
ation of CsA [35]. Because of the classification within
the HLH syndromes, etoposide, a chemotherapeutic
agent, is regularly used as this is part of the first line
treatment regimen designed for primary HLH [10].
However, due to possible harmful side-effects, etoposide
is by some considered as a last resort.
In the last decade, biologicals are increasingly used
as treatment of MAS, however with varying results
[56–58]. Based on the included literature, there is in-
sufficient evidence for the use of IVIG or anti-TNFα
therapy for MAS in sJIA.
IL-1 blocking therapy with anakinra is increasingly
used in MAS as well. In 2011, a case-series was pub-
lished, reporting on 8 (severe) cases of MAS in sJIA that
reached rapid remission on anakinra when conventional
therapy failed [37, 59, 60]. In addition, anakinra induced
remission of underlying disease and therefore seems ad-
vantageous over CsA. Another possible advantage of this
more targeted therapy could be a decrease of side effects
related to more extensive immunosuppressive therapy.
However, anakinra is not available in every country and
ideally its effectivity and safety should be compared to
the effects of ‘pulse’ steroidal therapy and/or CsA in a
randomised setting.
Conclusion
In conclusion, early diagnosis of MAS in sJIA, and
prompt start of treatment is crucial to improve outcome
but is often challenging in clinical practice. Recently,
consensus was reached on a robust set of widely avail-
able diagnostic criteria which scored good performance
in a large retrospectively collected database of sJIA pa-
tients with both active sJIA and MAS. As became clear
from this review, these diagnostic guidelines are cur-
rently the most useful diagnostic tool available. Further
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improvement in diagnosis will likely come from the
addition of promising biomarkers and will allow the
early use of targeted therapy.
Since evidence based recommendations on diagnosis
and treatment of MAS are still very limited, early expert
consultation is recommended as soon as MAS is
suspected.
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